From Vulnerability to Resilience
Study Efficiency
Start your first session to begin tracking. 🚀
Pomodoro Timer
Today's Focus
Core Narrative — Practice Daily (90 seconds)
"We started with a clinical paradox: some patients develop severe heart failure after low doses of anthracyclines, while others tolerate much higher cumulative doses with no cardiac injury. We hypothesized this reflects constitutional vulnerability — not treatment effects. Using patient-derived iPSC cardiomyocytes and 3D engineered heart tissues, we found pre-existing mitochondrial genome instability (~77% insertion-biased mutations in TOX vs ~54% in RES) and inadequate antioxidant defenses (GPX1↓, GSTM1↓), creating a constitutionally vulnerable cardiac phenotype. This shifts the paradigm: not 'how much drug causes heart failure' but 'who is already positioned close to cardiac failure thresholds.' Clinical implication: biomarker-guided personalized cardioprotection before the first dose."
22-Day Study Plan
April 28 – May 19 · 4 hrs/day · ADHD-optimized: 2 × 2-hour blocks
🧠 ADHD Protocol: Morning 09:00–11:00 · Afternoon 14:00–16:00 · Hard stop at 4h · Quiz after each block · Each task ≈ 30–45 min.
Active Recall Quiz
Spaced repetition · Stop when 90% correct · Progress saved to D1
50 Essential Papers
Track reading · Quiz per paper · Prioritized by defense relevance
2022 ESC Cardio-Oncology Guidelines
Lyon AR et al. Eur Heart J 2022 · Risk stratification · Drug-specific protocols · Clinical thresholds
Baseline CV Risk Categories (HFA-ICOS)
| Category | LVEF | Key Criteria | Thesis Context |
|---|---|---|---|
| Low | ≥55% | No CV risk factors, no CV disease | RES phenotype — buffer intact |
| Moderate | ≥50% | ≥2 uncontrolled CV risk factors OR 1 CV disease | Intermediate risk |
| High | 40–49% | Prior cardiotoxicity, severe valve disease, genetic CM | TOX phenotype risk zone |
| Very High | <40% | Decompensated HF, recent ACS, serious arrhythmia | Constitutional threshold crossed |
CTRCD Definition
New LVEF drop >10 percentage points to below 53%, with or without symptoms — OR — any new LVEF drop to <53% with new symptoms of HF
Subclinical CTRCD
GLS relative reduction >15% from baseline AND/OR new troponin elevation (above URL). LVEF still preserved.
Thesis Link
TOX patients cross this threshold at lower doses. mtDNA biomarker predicts this before GLS drops.
Drug-Specific Monitoring
| Drug | Baseline | During | After |
|---|---|---|---|
| Anthracyclines High | Echo+GLS, hsTnI, ECG | Echo q3 cycles; hsTnI each cycle (high risk) | 3mo, 6mo, 12mo, annual ×5yr |
| Trastuzumab | Echo, hsTnI, ECG | Echo q3 months | Echo 6mo + 12mo |
| CDK4/6 inhibitors | ECG (QTc <450ms!), electrolytes | ECG day 14 cycle 1, day 1 cycle 2, monthly ×3 | Echo if symptoms |
| ICIs | Troponin, ECG, echo | Troponin + ECG each cycle (high risk) | Annual echo ×5yr |
| VEGF inhibitors | BP every visit | BP monitoring; stop if grade 3 HTN | BP ×1yr |
Cardioprotection
ACEi + Carvedilol
Most studied. Start when LVEF 50–54% or GLS >15% relative reduction. Continue ≥6 months.
Dexrazoxane
Iron chelator. Recommended at >300 mg/m² doxorubicin equivalent. Reduces cardiotoxicity ~60–70%.
SGLT2 Inhibitors
Emerging evidence. Active trials. Thesis relevance: metabolic protection of failing cardiomyocytes.
ICI Myocarditis — Immediate Protocol
Incidence 0.5–1.5% · Case fatality up to 50% if fulminant · Every hour matters
| Step | Action | Why |
|---|---|---|
| 1 | Withhold ICI immediately | Stop ongoing immune damage |
| 2 | Methylprednisolone 1g/day IV ×3–5 days | Immunosuppression — delay = mortality |
| 3 | Cardiac MRI (T2 edema + LGE) | Confirms diagnosis, quantifies inflammation |
| 4 | Biopsy if uncertain (CD3/CD8+ infiltrate) | Definitive diagnosis |
| 5 | Refractory: mycophenolate / abatacept | Second-line immunosuppression |
Test Your Guidelines Knowledge
15 questions · Risk categories, CTRCD definition, drug protocols, ICI myocarditis
Opposition Committee
Defense order · May 21, 2026 · Know their lens, their papers, their questions
⚡ The Disarming Move: Reference each member's paper by name ("Your 2022 Nature paper on cGAS/STING…"). One sentence transforms examination into conversation.
Defense Strategy
The Three Laws
Acknowledge Before Defending
"That is an important limitation. We addressed it by…" — Never be defensive. Shows scientific maturity.
Data Before Opinion
Ground every answer in your actual figures before making interpretive claims.
Offer the Future
For every limitation, propose the specific experiment that would resolve it.